510(k) device
Thromborel S
Dade Behring, Inc. · Test, Time, Prothrombin (GJS, Class II) · First FDA decision Feb 20, 2001, newest Feb 20, 2001Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Thromborel S"
MAUDE reports
28
Brand "Thromborel S", since 2015
PubMed studies
44
Mentioning "Thromborel S"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Thromborel S
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- THROMBOREL S510(k)
K003870 · Decided Feb 20, 2001 · 67 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Thromborel S", any status and sponsor, newest update first.
No registered device study names "Thromborel S".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Thromborel S", and for the whole product code for context.
This brand
28 reports: 28 malfunction, 0 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
- THROMBOREL SMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
9610806-2026-00005 · Received Feb 19, 2026 · Event dated Jan 22, 2026
Device type: Test, Time, Prothrombin (GJS)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- THROMBOREL SMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
9610806-2025-00033 · Received Jul 31, 2025 · Event dated Jul 21, 2025
Device type: Test, Time, Prothrombin (GJS)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- THROMBOREL SMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
9610806-2025-00022 · Received Jun 24, 2025 · Event dated Jun 5, 2025
Device type: Test, Time, Prothrombin (GJS)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Thromborel S"[tiab]. The summary above synthesizes these.
- Multicenter evaluation of a new capillary blood prothrombin time monitoring system.
van den Besselaar AM, Breddin K, Lutze G, et al. · Blood Coagul Fibrinolysis · 1995Comparative Study, Multicenter Study
- Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent.
Kamal F, Othman HR · Am J Case Rep · 2025Case Reports
- End user evaluation of DG-PT L Rec, a human recombinant thromboplastin in liquid formulation.
Segarra N, Huguet J, Fernández-Forner B · Blood Coagul Fibrinolysis · 2017
- MiR-186-5p Downregulates NAMPT and Functions as a Potential Therapeutic Target for Sepsis-Induced Coagulation Disorders.
Shen H, Xie K, Peng M, et al. · Comput Intell Neurosci · 2022Retracted Publication
- International normalized ratio measurement during perioperative anticoagulation bridging with low-molecular-weight heparin in patients undergoing heart valve replacement surgery.
Rijvers L, Rijpma SR, van Wetten HB, et al. · Res Pract Thromb Haemost · 2024
- An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1).
Suzuki S, Yamashita T, Kasai H, et al. · Drug Metab Pharmacokinet · 2018Observational Study
- Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.
Kim B, Jang S, Lee YJ, et al. · J Thromb Thrombolysis · 2020
- Estimating the measurement uncertainties of the international sensitivity index of 12 thromboplastins through Monte Carlo simulation.
Lim YK, Kweon OJ, Lee MK, et al. · Thromb Res · 2023
- Performance evaluation of the microINR® point-of-care INR-testing system.
Joubert J, van Zyl MC, Raubenheimer J · Int J Lab Hematol · 2018Evaluation Study
- Specific determination of plasmatic thrombin activity.
Stief TW · Clin Appl Thromb Hemost · 2006
- Recombinant thromboplastin inhibition assay for the detection of lupus anticoagulant.
Zanon E, Saracino MA, Simioni P, et al. · Clin Lab Haematol · 1995
- Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions.
Orvim U, Roald HE, Stephens RW, et al. · Arterioscler Thromb · 1994
Other devices of this type
Also filed under product code GJS.
- microINR SystemIline Microsystems, S.L. · 510(k) 2025
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.